Interview with John Montgomery , CEO, Alphapharm
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
Address: Level 1, 30 The Bond, 30-34 Hickson Road, Millers Point NSW 2000
Tel: (602) 9298 3999
Web: http://www.alphapharm.com.au/
Alphapharm has been researching, developing and making generic medicines in Australia for more than 25 years. Millions of Australians take an Alphapharm generic medicine every day. Alphapharm has become the largest supplier of medicines to the subsidised PBS and Australia’s leader in generic medicines.
Alphapharm medicines are available Australia-wide. Alphapharm medicines are made to the highest global quality standards and exported to more than 50 countries, including those in Europe and the US.
Globally, Alphapharm is part of Mylan whose broad offering includes the world’s second largest portfolio of active pharmaceutical ingredients (APIs) and a powerful pipeline with more than 200 applications or dossiers pending regulatory approval. The structure of Alphapharm enables the company to leverage Mylan’s global platform while maintaining a very strong emphasis on meeting local market needs and expectations.
Cardiology, Pain Management, Osteoporosis, Smoking Cessation, Weight Management
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
Pharmaceutical policy issues played a major role in Australia’s recent national election. Shawview Consulting’s Brendan Shaw outlines the medicines issues that came under scrutiny during the campaign. It was the…
Writing in April edition of DIA’s Global Forum magazine, the University of New South Wales’s Richard Day looks at Australia’s National Medicines Policy (NMP) and how it is being reshaped…
Writing in the January edition of DIA’s Global Forum magazine, Julia Chan, David Liew, Jana Stojanova, and Chris McMaster of Austin Health, Melbourne and St. Vincent’s Hospital Sydney outline how…
In conversation in the November issue of DIA’s Global Forum magazine, Australian Pharmaceutical medical and scientific Professionals Association (APPA) Past President David Grolman highlights the contributions that Australia is already…
Regular PharmaBoardroom contributor Brendan Shaw outlines how his home country of Australia has so far successfully managed to avoid the worst of the COVID-19 pandemic, providing opportunities for the life…
In an exclusive new podcast, DIA Global Forum Australia/New Zealand Regional Editor Richard Day (University of New South Wales, Medicine, St. Vincent’s Hospital) and John Skeritt, Head of Australia’s Therapeutic Goods Administration (TGA),…
Janssen Australia & New Zealand’s Bruce Goodwin argues that greater adoption of patient-centric practices is beneficial to patients, companies and healthcare systems as a whole. Goodwin also gives his five…
Can you start by giving our readers a brief overview of the company’s history here and your most notable achievements? Initially the company was founded as a small distributor of…
Would you begin by outlining the role & importance of George Clinical within the George Institute, highlighting recent milestones & achievements? George Clinical is an important division of the Institute,…
Would you begin by giving an introduction to our international readers of the institute, highlighting recent milestones & achievements and the current focus areas of its research activities? Broadly speaking,…
For those that are not familiar with your name, would you start by introducing yourself? After obtaining my PhD in cardiovascular physiology I moved to Boston to work at MIT…
Rare Voices Australia is a new organisation that has been established after the national rare diseases symposium in 2011. Can you please begin with giving our readers an introduction to…
See our Cookie Privacy Policy Here
